A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone:
THE OUTBACK TRIAL (ANZGOG 0902, GOG 0274, RTOG 1174)

Current Status

<table>
<thead>
<tr>
<th>Group</th>
<th>Active sites</th>
<th>Pts randomised</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANZGOG</td>
<td>16</td>
<td>97</td>
</tr>
<tr>
<td>NRG Oncology</td>
<td>148</td>
<td>294</td>
</tr>
<tr>
<td>TOTAL</td>
<td>164</td>
<td>391</td>
</tr>
</tbody>
</table>

Message from the study chair

Dear Team,
Thanks to everyone for the ongoing hard work recruiting to the OUTBACK study. It is great to see that the study is now halfway recruited!

The study results were recently reviewed by the IDSMC for the planned 2\textsuperscript{nd} interim analysis of toxicity and I have been advised that they are satisfied with the progress of the study and recommend it continue as planned.

We are continuing to explore options to open the study in other countries with a greater burden of cervical cancer. Congratulations to Canada for getting well underway with recruitment there.

Best wishes,
Linda Mileshkin
Accrual graphs

Overall accrual

![Overall accrual graph](chart)

Monthly accrual

![Monthly accrual graph](chart)
InForm - How do I change an answer in response to a query in the database?

- Click on the answer field, rather than the query text
- Change the answer in the answer field
- Provide a reason for change
- Click on “Submit” at the bottom

Frequently Asked Questions (FAQ)

Q: If a cisplatin cycle is delayed by one week, should only 4 cycles be given in those 5 weeks instead of 5 (1 cycle omitted)?

A: If the patient is still receiving external beam radiotherapy in the 6th week, then the last cycle of cisplatin should be given, despite the week’s delay.

Q: If a patient’s weight changes more than 10%, do both paclitaxel and carboplatin need to be recalculated?

A: Yes, as per section 8.1 in the protocol both paclitaxel and carboplatin need to be recalculated.
Q: Are patients with clear cell histology eligible?
A: Yes, clear cell adenocarcinoma is a subset of adenocarcinomas.

Q: How do we calculate the tumour volume for the Nodal Assessment CRF?
A: Tumour volume \((\text{cm}^3 \times \text{Axial} \times \text{AP diameter in cm/0.52}) = \text{in cm}^3\).